Our interest in GPR55 as an inflammatory mediator and drug target was based on two pharmacological characteristics: 1) the recognition that this pro-inflammatory GPCR has a role in the production of peripheral neuropathy (Staton et al., 2008; Okine et al., 2020; Foss et al., 2021); and 2) the identification of both natural and synthesized cannabinoids as interactors with GPR55 (Marichal-Cancino et al., 2017; Bih et al, 2015). The gene discussed is GPR55; the disease is peripheral neuropathy.